Figure 2.

Construction of a comprehensive immunopeptidome atlas of human cancer, see also Figure S1 and Table S2

(A) MS/MS spectra numbers of the immunopeptidomic datasets included in this study.

(B) The distributions of sample number, PSM number and non-modified and modified peptide number for the nine cancer types and non-cancerous samples, respectively.

(C) Length distributions of the identified HLA class I and HLA class II non-modified peptides.

(D) Length distributions of the identified HLA class I and HLA class II modified peptides.

(E) Venn diagram comparing unique HLA class I peptide sequences from this study and SysteMHC Atlas.

(F) Venn diagram comparing unique HLA class II peptide sequences from this study and SysteMHC Atlas.

(G) Cumulative number of all distinct HLA class I peptides as a function of dataset publication time. Each dataset is denoted as dataset ID: dataset public time (#peptides).

(H) Cumulative number of distinct peptides for each of the top nine HLA class I alleles as a function of dataset publication time.